Michael Thomas Heffernan Sells 25,000 Shares of Collegium Pharmaceutical Inc (COLL) Stock

Collegium Pharmaceutical Inc (NASDAQ:COLL) Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $16.60, for a total transaction of $415,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Michael Thomas Heffernan also recently made the following trade(s):

  • On Monday, October 15th, Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00.

COLL opened at $17.38 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.75 and a debt-to-equity ratio of 4.17. Collegium Pharmaceutical Inc has a 1-year low of $13.70 and a 1-year high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The business had revenue of $70.20 million during the quarter, compared to the consensus estimate of $74.79 million. During the same quarter in the previous year, the business posted ($0.45) earnings per share. The firm’s revenue was up 485.0% on a year-over-year basis. Equities analysts anticipate that Collegium Pharmaceutical Inc will post -1.74 earnings per share for the current year.

Several equities research analysts recently issued reports on COLL shares. Janney Montgomery Scott set a $27.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Monday, August 6th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, August 8th. Cantor Fitzgerald decreased their price target on shares of Collegium Pharmaceutical from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, August 9th. BidaskClub downgraded shares of Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. Finally, HC Wainwright reiterated a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Collegium Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $31.71.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its position in shares of Collegium Pharmaceutical by 9.4% during the 1st quarter. Royal Bank of Canada now owns 28,238 shares of the specialty pharmaceutical company’s stock valued at $721,000 after purchasing an additional 2,437 shares during the period. Atria Investments LLC bought a new stake in shares of Collegium Pharmaceutical during the 2nd quarter valued at $201,000. Massachusetts Financial Services Co. MA raised its position in shares of Collegium Pharmaceutical by 1.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 419,656 shares of the specialty pharmaceutical company’s stock valued at $10,009,000 after purchasing an additional 5,818 shares during the period. Commonwealth Equity Services LLC raised its position in shares of Collegium Pharmaceutical by 23.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 29,539 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 5,640 shares during the period. Finally, Sheaff Brock Investment Advisors LLC raised its position in shares of Collegium Pharmaceutical by 133.8% during the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 27,000 shares of the specialty pharmaceutical company’s stock valued at $644,000 after purchasing an additional 15,450 shares during the period. Institutional investors and hedge funds own 94.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Michael Thomas Heffernan Sells 25,000 Shares of Collegium Pharmaceutical Inc (COLL) Stock” was originally posted by WKRB News and is the property of of WKRB News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.wkrb13.com/2018/11/18/michael-thomas-heffernan-sells-25000-shares-of-collegium-pharmaceutical-inc-coll-stock.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Article: Intrinsic Value and Stock Selection

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply